GlobalData on MSN
ALK’s EURneffy secures MHRA approval for anaphylaxis treatment
The authorisation extends access to a treatment option previously confined to injection-based administration.
A new risk score stratifies children’s risk for biphasic anaphylaxis and could reduce unnecessary emergency department ...
Standard intramuscular adrenaline doses failed to restore blood pressure in most participants exposed to a controlled histamine challenge mimicking severe anaphylaxis.
The MHRA’s approval of a lower dose of EURneffy means more children will have a needle-free option to treat anaphylaxis.
People who don't like to workout will sometimes joke that they're "allergic" to exercise. But what many don't realize is that ...
The FDA added a boxed warning about rare cases of anaphylaxis associated with the multiple sclerosis (MS) drug glatiramer acetate (Copaxone, Glatopa), the agency announced on Wednesday. The warning ...
Anaphylaxis is the most extreme form of severe allergic reactions which can be life threatening and requires emergency medical treatment. It can affect anyone of any age, sex, race and stature.
Biphasic anaphylaxis is a second anaphylactic reaction after successful treatment, without new allergen exposure. It can occur up to 72 hours later, often peaking within 8 to 11 hours. Symptoms can ...
Although many parents of infants worry about their child having a food allergy, there has not been a lot of research into the presentation of anaphylaxis in infants. A new study being presented at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results